Eris Lifesciences share price

Balanced risk
  • 39%Low risk
  • 39%Moderate risk
  • 39%Balanced risk
  • 39%High risk
  • 39%Extreme risk
  • 1,783.50(-0.38%)
    June 13, 2025 15:29:35 PM IST
    • NSE
    • BSE
  • Vol : 287.87K (NSE + BSE)
    Last 20 day avg : 384.00 K

Eris Lifesciences is trading -0.38% lower at Rs 1,783.50 as compared to its last closing price. Eris Lifesciences has been trading in the price range of 1,815.80 & 1,734.55. Eris Lifesciences has given 30.39% in this year & 8.43% in the last 5 days. Eris Lifesciences has TTM P/E ratio 54.75 as compared to the sector P/E of 24.72.There are 9 analysts who have initiated coverage on Eris Lifesciences. There are 5 analysts who have given it a strong buy rating & 3 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 93.84 Crores in its last quarter.Listed peers of Eris Lifesciences include J B Chemicals And Pharmaceutical (-1.44%), Wockhardt (-0.35%), Eris Lifesciences (-0.38%).The Mutual Fund holding in Eris Lifesciences was at 16.59% in 31 Mar 2025. The MF holding has increased from the last quarter. The FII holding in Eris Lifesciences was at 8.43% in 31 Mar 2025. The FII holding has increased from the last quarter.

  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Key Metrics

Updated on Jun 13, 2025, 03:52 PM UTC

  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    0.41
    Lower than industry
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    8.55
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    69.29
    Higher than historical values
  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    0.55
    Low volatility
  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    0.87
    Higher than industry
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    -
Price range
Day Range
Lowest
1,734.55
Highest
1,815.80
52 week range
Lowest
988.95
Highest
1,909.55
Eris Lifesciences Financials
Financials
Financials include key reports like the Profit & Loss Statement (P&L), Balance Sheet, and Cash Flow Statement, providing insights into a company's performance, financial health, and liquidity
View all
  • Income
  • Balance Sheet
  • Cash Flow
Loading...
Units in the chart are in crores
Insights
  • Financial
  • Valuation
    • financial-insightsCompany is profitable
    • financial-insightsThe company's revenue grew in March quarter by 28.02% from Rs 705.30 crore to Rs 550.93 crore, year-on-year
    • financial-insightsThe company has grown its March quarter profit by 32.24% from Rs 70.96 crore to Rs 93.84 crore, year-on-year
    • financial-insightsThe debt to equity of the company is higher than the industry median
    • financial-insightsCompany can comfortably pay off its interest obligations with its earnings
Eris Lifesciences Technical Analysis
Pivot Level - classic
Info
Key price levels (support and resistance) calculated using the previous day's high, low, and close, aiding in technical analysis and trading decisions
  • R1
  • 1,814.67
  • R2
  • 2,047.48
  • R3
  • 2,185.42
Pivot1,676.73
  • S1
  • 1,443.92
  • S2
  • 1,305.98
  • S3
  • 1,073.17
Short Term
Info
Considers price movement over the last 1-2 weeks
Not Available
Long Term
Info
Considers price movement over the last 6 months
Not Available
  • Very Bearish
  • Bearish
  • Neutral
  • Very Bullish
  • Bullish
Trends unavailable at the moment.
Eris Lifesciences Peers
Return Comparison
Peers Comparison
Names
Technical ratingPrice%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
J B Chemicals And Pharmaceutical
Moderately Bullish
1,720.00-1.4426,749.5640.137.560.730.19
Wockhardt
Bullish
1,777.45-0.3528,879.83-5.76-30.00
Eris Lifesciences
Bullish
1,783.50-0.3824,380.6565.548.070.4362.42
Alembic Pharmaceuticals
Moderately Bullish
997.650.7019,661.4533.723.721.120.90
Jubilant Pharmova
Bullish
1,094.15-2.7817,395.0834.172.90.4438.19
Eris Lifesciences Shareholding
View All
Shareholding Pattern
Breakdown of a company's ownership structure, showing stakes held by Promoters, Mutual Funds, FII(s) & Others.
    No Data
    Shareholding pattern for Eris Lifesciences is currently unavailable
    Please check back later.
    Shareholding Insights
    • InsightsPledged found - Promoter(s) have pledged 18.51% of shares.
    • InsightsPledging Flat - Promoter(s) pledging has not increased in last quarter.
    • InsightsPromoter(s) holds a high stake in the company at 54.85%
    • InsightsPromoter(s) have decreased the stake in the company in last 12 months
    • InsightsFIIs are invested in this company
    • InsightsFIIs holding has increased by 0.07 percentage points from previous quarter
    • InsightsMutual Funds holding has increased by 0.07 percentage points from previous quarter
    Mutual Fund Ownership
    View all
    UTI Healthcare Fund Regular Plan Growth
    NA
    • Amount Invested (Cr.) 32.35
    • % of AUM 3.04
    UTI Small Cap Fund Regular Growth
    2/5
    • Amount Invested (Cr.) 85.02
    • % of AUM 1.88
    UTI Mid Cap Fund Regular Plan Growth
    1/5
    • Amount Invested (Cr.) 137.72
    • % of AUM 1.18
    UTI Flexi Cap Fund Regular Plan Growth
    2/5
    • Amount Invested (Cr.) 233.44
    • % of AUM 0.92
    Motilal Oswal Nifty Smallcap 250 Index Fund Regular Growth
    NA
    • Amount Invested (Cr.) 4.12
    • % of AUM 0.45
    Eris Lifesciences Corporate Actions
    View all
    • Board Meetings
    • AGM
    • Dividends
    • Bonus
    • Split
    • Rights
    Meeting DatePurpose
    2025-05-19Audited Results
    2025-02-07Interim Dividend
    2025-02-04Quarterly Results
    2024-10-25Quarterly Results
    2024-08-02Quarterly Results
    About the company Eris Lifesciences
    • IndustryBiotechnology & Drugs
    • ISININE406M01024
    • BSE Code540596
    • NSE CodeERIS
    Eris Lifesciences Limited is an India-based pharmaceutical company. The Company is engaged in the manufacture and marketing of pharmaceutical products. The Company has a presence in major therapies like oral anti-diabetes, insulins, cardiovascular, vitamins/minerals and dermatology. Its flagship therapies include oral anti-diabetes, cardiovascular disease (CVD), and vitamins, minerals and nutrients (VMN). Its emerging therapies consist of dermatology, insulins, women’s health, central nervous system (CNS), oncology, and nephrology. Its portfolio of brands includes Glimisave, Eritel, LNBloc, Olmin, Crevast, Atorsave, Gluxit, Renerve, Zomelis, Cosvate, Tayo, Cyblex, Remylin, Tendia, Rabonik, Ginkocer, Psorid, Raricap, Serlift, and Onabet, among others. Its patient care initiatives (PCI) platform provides various healthcare solutions to its patients. The Company has a manufacturing plant located in Guwahati, Assam.
    • Management Info
    • Amit BakshiExecutive Chairman of the Board, Managing Director
    • Sachin ShahChief Financial Officer
    • Krishnakumar VaidyanathanChief Operating Officer, Executive Director
    • Milind TalegaonkarCompliance Officer, Company Secretary
    • Inderjeet NegiExecutive Director
    • Kaushal ShahExecutive Director
    Eris Lifesciences Share Price FAQs

    Eris Lifesciences is trading at 1783.50 as on Fri Jun 13 2025 09:59:35. This is -0.38% lower as compared to its previous closing price of 1790.25.

    The market capitalization of Eris Lifesciences is 24380.65 Cr as on Fri Jun 13 2025 09:59:35.

    The average broker rating on Eris Lifesciences is Strong Buy. The breakup of analyst rating is given below -

    • 5 analysts have given a strong buy rating
    • 3 analysts have given a buy rating
    • 1 analysts have given a hold rating
    • 0.00 analysts have given a sell rating
    • 0.00 analysts have given a strong sell rating

    The 52 wk high for Eris Lifesciences is 1909.55 whereas the 52 wk low is 988.95

    Eris Lifesciences can be analyzed on the following key metrics -

    • TTM P/E: 54.75
    • Sector P/E: 24.72
    • Dividend Yield: 0.41%
    • D/E ratio: 0.87

    Eris Lifesciences reported a net profit of 351.84 Cr in 2025.

    The Mutual Fund Shareholding was 16.59% at the end of 31 Mar 2025.